D. E. Shaw & Co. Inc. Lowers Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

D. E. Shaw & Co. Inc. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 217,813 shares of the specialty pharmaceutical company's stock after selling 47,789 shares during the period. D. E. Shaw & Co. Inc. owned 0.68% of Collegium Pharmaceutical worth $6,240,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter valued at $40,000. KBC Group NV increased its stake in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after acquiring an additional 982 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after acquiring an additional 316 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical during the fourth quarter worth about $230,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Wall Street Zen downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, Needham & Company LLC restated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $43.80.

Insider Buying and Selling

In other news, CFO Colleen Tupper sold 977 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the transaction, the chief financial officer now owns 164,269 shares in the company, valued at $4,928,070. This represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock valued at $2,334,994 over the last 90 days. Company insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ COLL traded down $0.34 during trading on Thursday, reaching $29.14. 20,616 shares of the company traded hands, compared to its average volume of 426,610. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a 50 day simple moving average of $28.15 and a 200-day simple moving average of $29.80. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The stock has a market capitalization of $936.17 million, a PE ratio of 12.58 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.45 EPS. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.